vs
Side-by-side financial comparison of Gossamer Bio, Inc. (GOSS) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
Gossamer Bio, Inc. is the larger business by last-quarter revenue ($13.8M vs $11.5M, roughly 1.2× TRANSACT TECHNOLOGIES INC). On growth, Gossamer Bio, Inc. posted the faster year-over-year revenue change (47.1% vs 11.9%).
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
GOSS vs TACT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.8M | $11.5M |
| Net Profit | $-47.2M | — |
| Gross Margin | — | 47.6% |
| Operating Margin | -333.6% | -10.1% |
| Net Margin | -342.3% | — |
| Revenue YoY | 47.1% | 11.9% |
| Net Profit YoY | -43.0% | — |
| EPS (diluted) | $-0.21 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.8M | $11.5M | ||
| Q3 25 | $13.3M | $13.2M | ||
| Q2 25 | — | $13.8M | ||
| Q1 25 | — | $13.1M | ||
| Q4 24 | — | $10.2M | ||
| Q3 24 | — | $10.9M | ||
| Q2 24 | $95.8M | $11.6M | ||
| Q1 24 | $0 | $10.7M |
| Q4 25 | $-47.2M | — | ||
| Q3 25 | $-48.2M | $15.0K | ||
| Q2 25 | — | $-143.0K | ||
| Q1 25 | — | $19.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-551.0K | ||
| Q2 24 | $49.2M | $-319.0K | ||
| Q1 24 | $-41.9M | $-1.0M |
| Q4 25 | — | 47.6% | ||
| Q3 25 | — | 49.8% | ||
| Q2 25 | — | 48.2% | ||
| Q1 25 | — | 48.7% | ||
| Q4 24 | — | 44.2% | ||
| Q3 24 | — | 48.1% | ||
| Q2 24 | — | 52.7% | ||
| Q1 24 | — | 52.6% |
| Q4 25 | -333.6% | -10.1% | ||
| Q3 25 | -369.4% | 0.1% | ||
| Q2 25 | — | -1.9% | ||
| Q1 25 | — | -0.1% | ||
| Q4 24 | — | -10.3% | ||
| Q3 24 | — | -7.7% | ||
| Q2 24 | 54.3% | -3.8% | ||
| Q1 24 | — | -12.2% |
| Q4 25 | -342.3% | — | ||
| Q3 25 | -362.7% | 0.1% | ||
| Q2 25 | — | -1.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -5.1% | ||
| Q2 24 | 51.4% | -2.8% | ||
| Q1 24 | — | -9.7% |
| Q4 25 | $-0.21 | $-0.11 | ||
| Q3 25 | $-0.21 | $0.00 | ||
| Q2 25 | — | $-0.01 | ||
| Q1 25 | — | $0.00 | ||
| Q4 24 | — | $-0.80 | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | $0.22 | $-0.03 | ||
| Q1 24 | $-0.19 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $136.9M | $20.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-122.8M | $31.1M |
| Total Assets | $172.2M | $44.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $136.9M | $20.4M | ||
| Q3 25 | $180.2M | $20.0M | ||
| Q2 25 | — | $17.7M | ||
| Q1 25 | — | $14.2M | ||
| Q4 24 | — | $14.4M | ||
| Q3 24 | — | $11.3M | ||
| Q2 24 | $354.5M | $11.1M | ||
| Q1 24 | $244.4M | $10.6M |
| Q4 25 | $-122.8M | $31.1M | ||
| Q3 25 | $-82.3M | $31.8M | ||
| Q2 25 | — | $31.3M | ||
| Q1 25 | — | $30.9M | ||
| Q4 24 | — | $30.6M | ||
| Q3 24 | — | $38.4M | ||
| Q2 24 | $81.5M | $38.5M | ||
| Q1 24 | $26.7M | $38.6M |
| Q4 25 | $172.2M | $44.8M | ||
| Q3 25 | $208.8M | $45.0M | ||
| Q2 25 | — | $44.5M | ||
| Q1 25 | — | $44.2M | ||
| Q4 24 | — | $44.0M | ||
| Q3 24 | — | $50.5M | ||
| Q2 24 | $373.4M | $50.4M | ||
| Q1 24 | $259.4M | $51.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.3M | $609.0K |
| Free Cash FlowOCF − Capex | — | $589.0K |
| FCF MarginFCF / Revenue | — | 5.1% |
| Capex IntensityCapex / Revenue | 0.0% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.3M | $609.0K | ||
| Q3 25 | $-36.2M | $3.6M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | — | $-161.0K | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | — | $327.0K | ||
| Q2 24 | $116.3M | $636.0K | ||
| Q1 24 | $-52.3M | $-1.5M |
| Q4 25 | — | $589.0K | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | — | $-171.0K | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | — | $259.0K | ||
| Q2 24 | — | $499.0K | ||
| Q1 24 | — | $-1.6M |
| Q4 25 | — | 5.1% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | — | 25.9% | ||
| Q1 25 | — | -1.3% | ||
| Q4 24 | — | 23.2% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | — | -14.9% |
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | 0.0% | 1.2% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.36× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
